Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Pharmaceuticals, The Jazz-Killer
07:33am, Thursday, 05'th Aug 2021
Avadel's once-nightly FT218 improves considerably over Xyrem's twice-nightly dosing.
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
08:00am, Wednesday, 07'th Jul 2021
DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
Avadel Pharmaceuticals - A Compelling Buy
09:40am, Friday, 14'th May 2021
Avadel Pharmaceuticals - A Compelling Buy
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2021 Results - Earnings Call Transcript
01:22pm, Monday, 10'th May 2021
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2021 Results - Earnings Call Transcript
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
08:00am, Monday, 10'th May 2021
DUBLIN, Ireland, May 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate desi
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
08:00am, Thursday, 29'th Apr 2021
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate des
DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
02:11pm, Tuesday, 09'th Mar 2021
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2020 Results - Earnings Call Transcript
FT218 assigned PDUFA target action date of October 15, 2021 FT218 assigned PDUFA target action date of October 15, 2021
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
06:20pm, Tuesday, 23'rd Feb 2021
DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate desi
Avadel Pharmaceuticals: Looking Good For Investors And Patients With Narcolepsy
03:19pm, Wednesday, 10'th Feb 2021
Avadel's flagship compound, FT218, is on its way towards approval with the FDA. FT218 once nightly dose has been proven more efficient and better accepted by patients than competing products.
Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
08:00am, Wednesday, 10'th Feb 2021
DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for
3 Fast-Growing Small Caps to Consider
10:34am, Sunday, 13'th Dec 2020
Investors who target growth may want to consider the following small-cap stocks, as they represent companies whose trailing 12-month net earnings per share improved significantly on a year-over-year b
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
08:00am, Monday, 07'th Dec 2020
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate des
